World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
35853
World Ranking
8600
National Ranking
840

Peter Johnson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Peter Johnson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 635 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Peter Johnson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Peter Johnson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Peter Johnson is affiliated with the University of Southampton in the United Kingdom and has contributed extensively to the field of medicine, with a specialization in pathology and forensic medicine, oncology, pulmonary and respiratory medicine, genetics, and molecular biology. Their research output spans over 313 publications, emphasizing lymphoma diagnosis and treatment, lung cancer treatments and mutations, chronic lymphocytic leukemia research, CAR-T cell therapy research, as well as COVID-19 related healthcare and clinical research studies.

Notable recent publications by Johnson include:

  • "Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study" (2020, BMJ)
  • "Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study" (2021, BMJ)
  • "Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up" (2020, Annals of Oncology)
  • "Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study" (2021, The Lancet)
  • "Discovering dominant tumor immune archetypes in a pan-cancer census" (2021, Cell)

Frequent co-authors collaborating with Johnson, reflecting repeated partnerships in research, are:

  • Andrew Davies
  • Emanuele Zucca
  • John Radford
  • Sally F. Barrington
  • David Hodgson

Johnson's publications frequently appear in the following venues, which indicate their primary outlets for disseminating research findings:

  • Blood
  • Hematological Oncology
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Blood Advances

In addition to journal articles, Johnson has contributed to book publications, including a title under Bloomsbury Academic eBooks titled "R. G. Collingwood and the Second World War" published in 2020.

The overarching topics of Johnson's work center on:

  • Lymphoma Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • COVID-19 and healthcare impacts
  • COVID-19 Clinical Research Studies

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

    Michael L. Wang;Simon Rule;Peter Martin;Andre Goy

  • Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study

    B. Coiffier;C. Haioun;N. Ketterer;A. Engert

  • Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    H Tilly;M Gomes da Silva;U Vitolo;A Jack

  • Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

    Peter Johnson;Massimo Federico;Amy A Kirkwood;Alexander Fossa

  • Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

    John Radford;Tim Illidge;Nicholas Counsell;Barry Hancock

  • European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma

    James M. Foran;Ama Z. S. Rohatiner;David Cunningham;Razvan A. Popescu

  • Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

    Mark S Cragg;Suzanne M Morgan;H T Claude Chan;B Paul Morgan

  • Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

    David Cunningham;Eliza A Hawkes;Andrew Jack;Wendi Qian

  • Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

    Andrés J M Ferreri;Kate Cwynarski;Elisa Pulczynski;Maurilio Ponzoni

  • Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

    Anas Younes;Laurie H. Sehn;Peter Johnson;Pier Luigi Zinzani

  • Clinical trials of antibody therapy.

    Martin J Glennie;Peter W.M Johnson

  • Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

    Michael L. Wang;Kristie A. Blum;Peter Martin;Andre Goy

  • Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.

    P. W. M. Johnson;A. Z. S. Rohatiner;J. S. Whelan;C. G. A. Price

  • Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

    Stephen A. Beers;Ruth R. French;H. T. Claude Chan;Sean H. Lim

  • Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

    Sally F. Barrington;Wendi Qian;Edward J. Somer;Antonella Franceschetto

  • Autocrine Production of Interleukin 6 Causes Multidrug Resistance in Breast Cancer Cells

    Dietrich Conze;Linda Weiss;Patricia Susan Regen;Alok Bhushan

  • Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

    Andres J. M. Ferreri;Kate Cwynarski;Elisa Pulczynski;Christopher P. Fox

  • Validation and comparison of two multiplex technologies, Luminex® and Mesoscale Discovery, for human cytokine profiling

    Ferdousi Chowdhury;Anthony Williams;Peter Johnson

  • First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

    Anton Hagenbeek;Ole Vestergaard Gadeberg;Peter Johnson;Lars Møller Pedersen

  • The mechanisms of action of rituximab in the elimination of tumor cells

    Peter W M Johnson;Martin J Glennie

Frequent Co-Authors

John Radford
John Radford University of Manchester
Martin J. Glennie
Martin J. Glennie University of Southampton
Graham Packham
Graham Packham University of Southampton
Mark S. Cragg
Mark S. Cragg University of Southampton
Emanuele Zucca
Emanuele Zucca Universita della Svizzera Italiana
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust
Freda K. Stevenson
Freda K. Stevenson University of Southampton
Peter Selby
Peter Selby University of Leeds
David C. Linch
David C. Linch University College London
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring healthcare careers goes beyond traditional medicine. Many students combine flexibility with career growth by pursuing online degrees in related fields. For those already working as registered nurses, cost is a significant consideration—see an in-depth guide to rn to bsn online cost to help plan your budget.

Individuals without prior nursing backgrounds looking to enter the field quickly may consider direct entry online msn programs. These programs are designed for career changers and can streamline your pathway to advanced nursing degrees.

Admission can also be a concern. If you’re looking for accessible options, some recommend exploring nursing programs with high acceptance rates, helping you find institutions with less stringent entry requirements.

Beyond nursing, medical billing and coding is another in-demand healthcare career accessible online. Learn about medical billing and coding online schools that accept financial aid, making it more affordable to start this vital administrative role.

Best Scientists Citing Peter Johnson

Trending Scientists

Recently Published Articles